Objective: We aimed to analyze the association between morphine and in-hospital outcomes in invasively managed ST elevation myocardial infarction (STEMI) and non-ST elevation acute coronary syndrome (NSTE-ACS) patients.
myocardial demand, have resulted in longstanding support by both the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) and the European Society of Cardiology (ECS) for the treatment of nitrate resistant chest pain due to acute myocardial infarction (MI). [3] [4] [5] [6] Despite the utilization of this agent in up to 30% of ACS patients, 7 there is limited evidence supporting the use of morphine in this cohort.
Furthermore, in 2005, a concerning retrospective observational analysis of 57 039 patients from the CRUSADE registry found that morphine recipients with non-ST elevation acute coronary syndromes (NSTE-ACS) had a significantly higher likelihood of recurrent MI [odds ratio (OR), 1 .34], death (OR, 1.48), and the composite endpoint of death or recurrent MI (OR, 1.44) during the initial admission. 7 However, only 36.5% of the patients included in this registry received percutaneous coronary intervention (PCI). As such, it is possible that the association between morphine and increased mortality in this study may be due to its administration in palliative or pre-terminal care.
Furthermore, since then, smaller observational studies in both ST elevation myocardial infarction (STEMI) and NSTE-ACS cohorts have also challenged this association of worse outcomes. [8] [9] [10] Yet, recent emerging evidence, including a small randomized controlled trial, suggests that morphine may inhibit and delay the absorption of oral anti-platelet agents with resultant delay in time to maximal platelet inhibition. [11] [12] [13] [14] Given the importance of rapid platelet inhibition in ACS, this may have significant implication on clinical outcomes.
In light of these concerns, we have undertaken a large single center retrospective analysis of both STEMI and NSTE-ACS patients undergoing coronary angiogram +/− PCI comparing inpatient outcomes in patients who received morphine and those who did not specifically in patients managed invasively. was defined as the date and time the first device was activated, be it a balloon, stent, or thrombectomy device. In the rare case that the lesion could not be crossed, the time of guidewire introduction was used.
| METHODS

| Study population
All
| Clinical outcomes
Clinical outcomes recorded included inpatient mortality, post procedure cardiogenic shock, post procedure acute renal failure, length of hospital stay, and infarct size as measured by peak troponin level.
| Statistical analysis
Patient characteristics and in-hospital clinical outcomes were compared across two groups, patients who received morphine and patients who did not receive morphine. Means +/− standard deviations were reported for continuous variables and frequencies with percentages for categorical variables. Student's t-tests were used to check for differences for continuous variables and chi-square tests were used for categorical variables.
There were two sets of multivariate analyses, one without propensity score matching and one with propensity score 1:1 matching. For the first set of analyses, we compared patients who received morphine to those who did not receive morphine with respect to outcomes. Logistic regression was used for binary outcomes (inhospital mortality, post-procedural cardiogenic shock, and postprocedural renal failure). Linear regression was used for continuous outcomes (length of hospital stay and infarct size, as measured by peak troponin level) Each outcome was reported as 1) unadjusted, 2)
adjusted for age and sex, and 3) adjusted for age, sex, body mass index, family history of coronary artery disease, shock at the start of percutaneous coronary intervention, hypertension, diabetes, smoking status, hypercholesterolemia, heart rate, systolic blood pressure, door to balloon time, prior coronary artery bypass grafting, congestive heart failure, cerebrovascular disease, and renal insufficiency.
As an additional method of accounting for nonrandom morphine treatment assignment, we adjusted for factors favoring selection of one treatment over another by using propensity scores. NSTE-ACS patients who received morphine were younger, had a higher prevalence of cerebrovascular disease, peripheral vascular disease, prior PCI, MI, congestive heart failure, and valvular surgery (Table 2 ).
| Morphine versus no morphine: in-hospital outcomes
In unadjusted outcomes, STEMI patients who received morphine had a lower in-hospital mortality (4.18% vs. 7.54%, OR 0.53 P = 0.03) and smaller infarct size (mean troponin level 0.75 ng/mL vs. 1.29 ng/mL, P = 0.02) ( Table 3) in non-morphine recipients, P = 0.07). There was no difference in the incidence of early stent thrombosis (2.2% in morphine group vs. 1.6%
in non-morphine recipients, P = 0.47) or of late stent thrombosis between each group (1.1% in morphine group vs. 1.2% in nonmorphine recipients, P = 0.91).
In the NSTE-ACS cohort, patients who received morphine had higher post-procedure acute renal failure (4.25% vs. 2.13%, OR 2.04, P = 0.02), longer length of hospital stay (mean 6.58 days vs. 4.78, P < 0.0001) and larger infarct size (mean peak troponin 1.16 ng/mL vs.
0.90 ng/mL, P = 0.05) ( Table 4 ). There was no statistical difference in in-hospital mortality between the morphine and non-morphine NSTE-ACS cohorts (3.77% vs. 2.51%, respectively, OR 1.53, P = 0.17) or cardiogenic shock (0.71% vs. 0.84% respectively, OR 0.85, P = 0.80).
After adjusting for basic characteristics, length of hospital stay (P < 0.0001) and infarct size (P = 0.02) remained significant (Table 4) .
NSTE-ACS patients who received morphine had an increased frequency of coronary thrombus (13% in morphine recipients vs. 8%
in non-morphine recipients, P = 0.002). There was no difference in the incidence of early stent thrombosis (0.7% in morphine group vs. 0.8%
in non-morphine recipients, P = 0.79) or of late stent thrombosis between each group (0.9% in morphine group vs. 1.2% in nonmorphine recipients, P = 0.64).
| Propensity score matched cohorts
Two propensity score-matched cohorts of 107 patients with similar baseline characteristics were built from the STEMI cohort (see supplementary material for list of variables, Table S1 ). In adjusted outcomes, inpatient mortality was similar between those STEMI patients who received morphine and those who did not (8% vs. 11%, respectively, OR: 0.73, P = 0.34). There was no difference in length of hospital stay (6.98 ± 10.17 days vs. 7.71 ± 13.11 days, P = 0.81) or infarct size as measured by troponin level (1.11 ± 2.65 vs. 1.84 ± 4.68, P = 0.67) between the morphine and non-morphine recipients, respectively (Table 5 ).
In the NSTE-ACS cohort, two propensity score-matched cohorts of 306 patients with similar baseline characteristics was created. In adjusted outcomes (Table 6) , NSTE-ACS patients who received morphine had a trend towards increased mortality (5% vs. 2%, OR:
2.36, P = 0.06). Notably, morphine recipients had larger infarct size as measured by troponin (1.14 ± 1.92 ng/mL vs. 0.83 ± 1.49 ng/mL, P = 0.01) and longer hospital stay (6.5 ± 6.82 days vs. 4.89 ± 5.36 days, P = 0.004).
| DISCUSSION
In our large single center retrospective study, NSTE-ACS patients who were recipients of morphine had 1) larger infarct size, 2) prolonged hospital stay, and 3) a trend towards increased mortality. In contrast, in STEMI patients who were recipients of morphine, there was no such signal of adverse outcomes.
Given our focus on patients invasively managed with PCI, our study is consistent with and adds to the growing body of evidence to suggest morphine may be associated with harm in NSTE-ACS patients. 7 The largest retrospective study in NSTE-ACS patients which included 57 039 patients from the CRUSADE registry, found that patients treated with morphine had a higher adjusted risk of death catheterization. Interestingly, the frequency of coronary thrombus was significantly higher among morphine recipients in the NSTE-ACS cohort with a trend towards significance in the STEMI cohort. It is plausible that inadequate platelet inhibition as a result of morphine administration may have contributed to the higher thrombus rates. As our study was retrospective and observational in nature, these negative outcomes may be explained by associated confounders.
However, the association between morphine and increased mortality, infarct size and hospital stay in NSTE-ACS patients was also seen in propensity matched cohorts. Nevertheless, it is impossible to account for all confounding factors with propensity analysis.
Mechanically, it is also plausible that the hemodynamic effects of morphine; reducing heart rate, decreasing blood pressure, and reducing venous return through venodilatation, might be beneficial in STEMI patients, where elevated sympathetic drive can be significant and detrimental. 15 In unadjusted outcomes, mortality rates were lower in STEMI patients who received morphine and our study may have been underpowered to truly assess this clinical endpoint. Supporting this hypothesis, a retrospective study by lakobishvilli et al. using
propensity score analysis of 249 matched STEMI pairs, found that the rate of 30-day death was lower in the group that had received morphine (2.4% vs. 6.2%, P = 0.04), and this trend persisted after logistic regression analysis (odds ratio 0.40, 95%CI 0.14-1.14, P = 0.09). 9 Again such benefit did not extend to the NSTE-ACS cohort in their study. Of the 95 matched NSTE-ACS pairs, no difference was found in the 30-day death rate (2.2% for patients receiving morphine vs. 6.3% in those who did not, P = 0.16). 9 Accordingly, we believe the current ACCF/AHA guidelines provide a sensible guidance to physicians, with morphine sulfate considered the "drug of choice for pain relief" in STEMI patients, albeit without providing a formal class of recommendation. 3 The guidelines provide a Class IIb recommendation (level of evidence B) for the use of morphine sulphate to alleviate pain in patients presenting with NSTE-ACS. 4 While placebo controlled randomized trials would provide more clarity on morphine's benefit and safety in these cohorts, due to the ethical requirements for analgesia in the control groups, such trials Prior renal failure, n (%) 91 (7) 28 (7) 0.83
Prior valvular surgery, n (%) 37 ( 
| Study limitations
The most significant limitation of our study is the non-randomized retrospective nature of our investigation. As a result, other unmeasured confounding factors may have influenced the out-
comes. An unmeasured factor such as significant chest pain could have influenced morphine administration and also be associated with larger infarct size. However, while the severity of chest pain has been associated with infarct size, 16 such an effect is inconsistent. For example, patients with diabetes mellitus frequently exhibit mild symptoms while infracting large areas of myocardium. Furthermore, the specific cause of death was not recorded in our study. This warrants further investigation as death due to stent thrombosis may suggest insufficient platelet inhibition secondary to morphineinduced impaired antiplatelet agent absorption. Additional limitations of our study include the lack of long-term follow up, absence of mechanistic investigation in our study, uncertainty of morphine dosages administered and the limited power of our propensity matched analysis. Finally, although patients with ST depressions in the anterior leads, routinely receive a posterior EKG to assess for a posterior MI in our center, it is possible that some patients with left circumflex coronary artery occlusion were misdiagnosed as an NSTE-ACS when in fact they may have suffered a STEMI.
| CONCLUSION
In a large retrospective study, morphine was associated with larger infarct size, a longer hospital stay and a trend towards increased mortality in NSTE-ACS patients but had no adverse effect on inhospital outcomes in STEMI patients.
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